Xtant plans to issue 20 million shares of common stock at $0.75 per share.
In the last reported quarter, the company said it is facing robust demand across the biologics and fixation products.
The closing of the private placement is expected to occur on or about July 6, 2023, subject to the satisfaction of customary closing conditions.
The company plans to expand the total addressable orthobiologic market opportunity to drive future growth.
Price Action: XTNT shares are trading lower by 4.29% to $0.89 on the last check Monday.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
